Ionis Pharmaceuticals Inc IONS
For three decades, we have invented medicines that bring better futures to people with serious diseases. 10-K, Item 1
- Employees
- 1,402
- Headquarters
- Carlsbad, CA
- CEO
- Brett P. Monia
- Next results
- around Jan 11, 2027
IONS among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
16 new risk paragraphs and 1 accounting fact worth reading about. 10-K filed Feb 26, 2026 against Feb 19, 2025.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
10 checks on the latest 10-K. Checks, not verdicts.
1fact worth reading about the other 9 checks found nothing to note
-
Critical audit matters changedNew this year: Auditing the (“How We Addressed the Matter in Our Audit We obtained an understanding and evaluated the design and tested the operating effectiveness of controls over the accounting for accrued clinical development expenses. This included controls over management's assessment of the assumptions and accuracy of data”); Company’s accruals for clinical and contract research organization costs is (“How We Addressed the Matter in Our Audit We obtained an understanding and evaluated the design and tested the operating effectiveness of controls over the accounting for accrued clinical development expenses. This included controls over management's assessment of the assumptions and accuracy of data”). No longer listed: Auditing the Company’s accruals for clinical and contract research organization costs is especially complex as the information necessary to estimate. Same as last year: Estimated Liability for Clinical Development Costs
-
Cash from operations −$268.6M vs net income −$381.4M (FY ending Dec 31, 2025)
8 more checks with nothing to note
-
Inventory -19.7% ($12.5M to $10.0M) vs revenue +33.8% ($705.1M to $943.7M), -53.5 pts apart
-
Same auditor in both 10-Ks: Ernst & Young LLP
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
16 paragraphs in Risk Factors that were not in the 10-K filed Feb 19, 2025. Quoted as filed.
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
Further, we believe that future coverage, reimbursement and pricing will likely be subject to increased restrictions both in the U.S. and in international markets. In the U.S., recent health reform measures have resulted in reductions in Medicare and other healthcare funding, and there have been several recent U.S. Congressional…
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
For example, while we continue to activate sites in the U.S., Canada, U.K., Australia and Japan, we revised and resubmitted the study protocol for the REVEAL study of obudanersen to address changes requested by EU regulators and plan to initiate EU sites for this study in 2026. Importantly, we believe we are on track to complete…
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
In addition, our development and commercialization activities could be harmed or delayed by staffing shortages or a shutdown or other significant disruption of the U.S. government, including the FDA or the U.S. PTO.
-
Item 1A · new paragraph · not in the 10-K filed Feb 19, 2025 10-K, ITEM 1A
We use artificial intelligence in certain aspects of our business, and challenges with properly managing its use could adversely affect our business. We incorporate artificial intelligence, or AI, solutions into certain aspects of our business, and applications of AI may become important in our operations over time. Our competitors or…
New risk paragraphs, against peers
Latest 10-K of each, Health care companies closest in revenue
Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.
Financial performance
Last 4 fiscal years · 10-K XBRL
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $587.4M | $787.6M | $705.1M | $943.7M |
| Net income | −$269.7M | −$366.3M | −$453.9M | −$381.4M |
| Operating cash flow | −$274.4M | −$307.5M | −$500.9M | −$268.6M |
| Free cash flow | −$290.1M | −$331.3M | −$546.2M | −$320.0M |
Revenue, FY2016 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$943.7M ▲ 33.8% in FY2025−$381.4M in FY2025−$320.0M in FY2025
Recent filings
5 filings in the last 30 days · SEC EDGAR
-
BuyNov 13, 2026Hayden Michael R (Director) bought $148K open-market purchase on Nov 10, 2026
-
8-KNov 9, 2026Quarterly results 8-K item 2.02
-
10-QNov 9, 2026Quarterly report (10-Q) period ended Sep 30, 2026
-
8-KOct 23, 2026Regulation FD disclosure, Other events 8-K items 7.01, 8.01
-
8-KOct 21, 2026Regulation FD disclosure, Other events 8-K items 7.01, 8.01
About the company
Ionis Pharmaceuticals Inc, Carlsbad, CA · from the 10-K filed Feb 26, 2026
For three decades, we have invented medicines that bring better futures to people with serious diseases. As a pioneer in RNA-targeted medicines with a deep understanding of disease biology and an industry-leading drug discovery technology, we are driven to deliver innovative, life-changing advances for patients. In the last year, we delivered on our strategy to create accelerating value for all our stakeholders. With two independent commercial launches now underway, we transitioned into a fully integrated commercial-stage biotechnology company.
- Headquarters
- Carlsbad, CA
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 9, 2026
- Incorporated in
- CA
Employees, at the top of the page: "As of February 19, 2026, we employed 1,402 people, the vast majority of whom reside in the U" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
The 10-K filed Feb 26, 2026 (open at SEC), compared with the 10-K filed Feb 19, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/IONS/export.csv") into a cell.